TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06581731
Drug: remimazolam combined with remifentanil
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients in this group will receive a bolus of remimazolam 5 mg intravenously, and then a dose of 0.1 μg/kg/min remifentanil and 0.5 mg/kg/h remimazolam via separate syringe pumps.
Study: NCT06581731
Drug: dexmedetomidine combined with remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will receive a loading dose of dexmedetomidine 1 μg/kg over 10 minutes intravenously, and then a dose of 0.1 μg/kg/min remifentanil and 0.5 μg/kg/h dexmedetomidine via separate syringe pumps.
Study: NCT06398730
Drug: GEH200520 Injection and GEH200521 (18F) Injection
Normalized name: INFLAMMATION AND INFECTION DETECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of GEH200520 Injection followed by GEH200521 (18F) Injection
Study: NCT06661915
Drug: Decitabine and Cedazuridine
Normalized name: cedazuridine / decitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05049707
Drug: IV magnesium sulfate
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 grams magnesium in 500 cc normal saline delivered at a rate of 15 mg/kg/hr
Study: NCT05447195
Drug: CAN008
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in this study is divided into four periods. Period 1 (W1-W6) is the triple therapy period in which subjects in both groups will be given CAN008 + RT + TMZ. Period 2 (W7-W10) is the treatment-free (rest) period in which subjects do not receive any study drug/therapy. Period 3 (W11-W58) is the CAN008+TMZ maintenance therapy period in which subjects in both groups are given CAN008+TMZ. Period 4 (after W59) is the monotherapy period in which subjects are given CAN008 IV infusion weekly until disease progression.
Study: NCT05447195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in this study is divided into four periods. Period 1 (W1-W6) is the triple therapy period in which subjects in both groups will be given placebo + RT + TMZ. Period 2 (W7-W10) is the treatment-free (rest) period in which subjects do not receive any study drug/therapy. Period 3 (W11-W58) is the placebo+TMZ maintenance therapy period in which subjects in both groups are given placebo+TMZ. Period 4 (after W59) is the monotherapy period in which subjects are given placebo IV infusion weekly until disease progression.
Study: NCT06252870
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15 mg/m² on Day+1 after graft (=Day0) 10 mg/m² 3 days on Day+4/Day+6/Day+11 after graft (=Day0)
Study: NCT06252870
Drug: Post-Transplant Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg intravenous 2 days on Day+3/Day+5 after graft (=Day0)
Study: NCT06252870
Drug: Cycophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditioning regimen: 14.5 mg/kg intravenous 2 days on Day-6/Day-5 before graft (=Day0)
Study: NCT05925452
Drug: GenaKumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: GenaKumab 3.0mg/kg dose group : GenaKumab 3.0 mg/kg, Subcutaneous injection, Q4w； GenaKumab 4.0 mg/kg dose group : GenaKumab 4.0 mg/kg, Subcutaneous injection, Q4w
Study: NCT05386550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 3 cycles of oral solution of placebo matched to Xevinapant (Debio 1143) once daily from Day 1 to 14 per 3-week cycle in combination with radiotherapy followed by 3 cycles of monotherapy of placebo matched to Xevinapant (Debio 1143) from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).
Study: NCT06329063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo (oral spray)
Study: NCT05587231
Drug: Dextenza 0.4Mg Ophthalmic Insert
Normalized name: Dextenza 0.4mg Ophthalmic Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: The experimental group will have the Dextenza Insert implanted immediately after surgery
Study: NCT05202574
Drug: Intravenous drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous drug injection
Study: NCT06571591
Drug: CT-L03 Group 1
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, QD, oral administration
Study: NCT06571591
Drug: CT-L03 Group 2
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, QD, oral administration
Study: NCT06571591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, QD, oral administration
Study: NCT04137588
Drug: Antiangiogenesis Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: antiangiogenesis agents plus chemotherapy as first line treatment
Study: NCT04987996
Drug: GR-MD-02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive up to seventeen doses of GR-MD-02 intravenously over 85 Days.
Study: NCT04987996
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive up to seventeen doses of placebo intravenously over 85 Days.
Study: NCT03335072
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mass Drug Administration
Study: NCT00260767
Drug: HEC placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00754949
Drug: 1% Azithromycin and 0.1% Dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
Study: NCT00754949
Drug: 1% Azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
Study: NCT06151587
Drug: QLM3004 Concentration 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of QLM3004 Ophthalmic Solution~1 drop in each eye at bedtime
Study: NCT06151587
Drug: QLM3004 Concentration 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose of QLM3004 Ophthalmic Solution~1 drop in each eye at bedtime
Study: NCT06151587
Drug: QLM3004 Concentration 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of QLM3004 Ophthalmic Solution~1 drop in each eye at bedtime
Study: NCT04603495
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets are designed to match pelabresib tablets. Each placebo tablet contains no active pharmaceutical ingredient and is visibly identical to experimental drug in size, shape, and packaging. Placebo dosing follows the same dosing conventions as pelabresib.
Study: NCT06659562
Drug: HER-096
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a single dose via s.c. injection
Study: NCT06659562
Drug: HER-096
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as multiple doses via s.c. injection. Administered twice a week (2 doses/week) during a 4-week period.
Study: NCT06659562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as multiple doses via s.c. injection. Administered twice a week (2 doses/week) during a 4-week period.
Study: NCT04739618
Drug: Keytruda Injectable Product
Normalized name: Keytruda Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitor antibody
Study: NCT04739618
Drug: Yervoy Injectable Product
Normalized name: Yervoy Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CTLA-4 antibody
Study: NCT06372522
Drug: Pitocin Injectable Product
Normalized name: Pitocin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: The primary dose of oxytocin is 1.0 mU/min, with an incremental increase by 2.5 mU/min every 30 minutes, until 20.0 mU/min, tittered to a target of 3-5 contractions in a 10-minute period, or active labor (dilatation \> 6 cm).
Study: NCT05840952
Drug: ALG-097558
Normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
Approvals — FDA: no, EMA: no, PMDA: no
Description: single or multiple doses of ALG-097558
Study: NCT05840952
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single or multiple doses of placebo
Study: NCT05840952
Drug: ALG-097558 in solution formulation
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALG-097558 in solution administered in fasted state
Study: NCT05840952
Drug: ALG-097558 in tablet formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALG-097558 in tablet administered in fasted and fed state
Study: NCT06252961
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 5 days
Study: NCT05385887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT05406219
Drug: BAY2395840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release (IR) tablet, oral administration
Study: NCT05978492
Drug: TXN10128
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive TXN10128 capsules orally once daily.
Study: NCT05804656
Drug: CKDB-501A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection CKDB-501A
Study: NCT05804656
Drug: Botox®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection Botox®
Study: NCT04847752
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: the dosage and duration
Study: NCT04847752
Drug: PCSK9 inhibitor
Normalized name: PCSK9 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: the dosage and duration
Study: NCT05859412
Drug: Steroid injection (Depomedrone 40mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid injection (Depomedrone 40mg) into the carpal tunnel as per standard practice in patients with carpal tunnel syndrome
Study: NCT06052254
Drug: 6 cm2 - 1 Active and 1 Placebo DMTS Patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Active and 1 Placebo DMTS patches applied to the upper back followed 7 days later by another application of 1 Active and 1 Placebo DMTS patches. Each application will be worn for 4 days (96 hours)
Study: NCT06052254
Drug: Placebo - 2 Placebo DMTS Patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 Placebo DMTS patches applied to the upper back followed 7 days later by another application of 2 Placebo DMTS patches. Each application will be worn for 4 days (96 hours)
Study: NCT04775862
Drug: investigator choice re-challenge with anti EGFR Rx
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upon second progression, patients will be enrolled into the study as per inclusion criteria and consent, and a cfDNA blood test will be drawn, and RAS status will be examined. If RAS is wildtype, then the investigator will decide whether to re-challenge with an anti EGFR antibody , or give SOC third line chemotherapy (Regorafenib or TAS-102).
Study: NCT05981001
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered at 60 mg/kg IV daily over approximately two hours for two days. Cyclophosphamide will be initiated seven days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
Study: NCT04945707
Drug: Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferric derisomaltose (Monoferric) 1000 mg X1 (for subject \<50 kg, 20 mg/kg
Study: NCT04945707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT04587843
Drug: Contrave 8Mg-90Mg Extended-Release Tablet
Normalized name: Contrave 8mg-90mg Extended-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each Contrave Extended Release Tablet contains 8Mg of naltrexone HCl and 90Mg of bupropion HCl and will be administered orally. Total daily dose is 32Mg / 360Mg.~Participants randomized to the treatment arm will be administered 4 Contrave tablets a day for 1 year (2 tablets taken twice a day).
Study: NCT04587843
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be administered orally. Participants randomized to the control arm will be administered 4 placebo tablets a day for 1 year (2 tablets, taken twice a day).
Study: NCT06014606
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral formulation
Study: NCT04752566
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered via IV infusion once a week for 4 weeks.
Study: NCT06132477
Drug: GLP-1 receptor agonist
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized to continue or discontinue GLP-1 receptor agonists after bariatric surgery
Study: NCT05237791
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline 100ml (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)
Study: NCT05935891
Drug: CBD-dominant
Approvals — FDA: no, EMA: no, PMDA: no
Description: product contains 2210 mg CBD and less than 0.3% THC per 1.5 ounce jar. Patients will be provided a 2-week supply of creams (3 jars for each 14 day interval) by Vireo Health, according to the randomization arm. Patient will be instructed to apply the topical products using the 1.25cc spoon provided (there are approximately 35 scoops per 1.5oz jar). The patient will apply one scoop of cream to the back of each hand and then rub into the entire hand, wrist, and all fingers. After the 14 day assessment, patients will be transitioned to a two-week open label extension that allows them to choose their preference of either Red XS or Violet cream at no cost.
Study: NCT05935891
Drug: THC dominant
Approvals — FDA: no, EMA: no, PMDA: no
Description: contains 375mg THC and less than 20mg CBD per 1.5 ounce jar. Patients will be provided a 2-week supply of creams (3 jars for each 14 day interval) by Vireo Health, according to the randomization arm. Patient will be instructed to apply the topical products using the 1.25cc spoon provided (there are approximately 35 scoops per 1.5oz jar). The patient will apply one scoop of cream to the back of each hand and then rub into the entire hand, wrist, and all fingers. After the 14 day assessment, patients will be transitioned to a two-week open label extension that allows them to choose their preference of either Red XS or Violet cream at no cost.
Study: NCT05577312
Drug: BRL-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A enhancer site
Study: NCT05718167
Drug: TQB2450
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 is a humanized monoclonal antibody targeting the programmed death ligand 1 (PD-L1), which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, making T cells recover their activity, thereby enhancing the immune response.
Study: NCT05105750
Drug: aspirin 100 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg aspirin for at least 3 days followed by aspirin 100 mg/d
Study: NCT05043792
Drug: TT-00920 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TT-00920 Placebo Tablets
Study: NCT04549116
Drug: Placebo Vaginal gel with applicator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal gel Placebo, once daily (QD) intravaginally
Study: NCT04549116
Drug: Placebo injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injectable solution, BID SC Injection every 12 hours
Study: NCT05158335
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single SC dose or repeated SC doses of placebo.
Study: NCT05411588
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05249933
Drug: Deyou; Beijing Tide Pharmaceutical Co, China, containing 20,000 iu pronase granules combined with 1 g NaHCO3 to maintain the intragastric PH at 6-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drink Deyo with 200ml warm water 25 minutes before swallowing the capsule to remove mucus in the stomach.
Study: NCT06117969
Drug: Xiangshao granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4g po tid
Study: NCT04955223
Drug: Yinhu Qingwen Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: For mild and common patients, take 1 bag 2 times a day. For severe patients, take 1 bag 3 times a day.
Study: NCT05680480
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo weekly in addition to SOC for 48 weeks.
Study: NCT04580368
Drug: CFTR Modulators
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with rare mutations will receive active therapy in N-of-1 design with participants serving as their own control
Study: NCT05699993
Drug: IBI351
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI351 was administered orally
Study: NCT06601517
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose; Administered orally
Study: NCT06601517
Drug: HDM1002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06604546
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 IU group D1:Placebo+500 ml Lactated Ringer's (LR)(Subject's left or right leg)； D2:Placeboe+250 ml Lactated Ringer's (LR)(Subject's left or right arm)； D3:Placebo+500 ml Normal Saline (NS)(Subject's left or right leg)； 385 IU group D1:Placebo+250 ml Lactated Ringer's (LR)(Subject's left or right arm)； 1500 IU group D1:Placebo+250 ml Lactated Ringe's (LR)(Subject's left or right arm).
Study: NCT06592495
Drug: Period 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWJ1589 or DWC202315
Study: NCT06592495
Drug: Period 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWJ1589 or DWC202315
Study: NCT06592495
Drug: Period 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWJ1589 or DWC202315
Study: NCT06608329
Drug: HDM1002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, administered orally. The study is a randomized, open-label, single dose, 3-period, 3 sequence, crossover design.
Study: NCT04942015
Drug: Placebo of Honghuaruyi Wan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honghuaruyi Wan simulation agent. Made of starch,dextrin and edible pigment from Tibet Qizheng Tibetan Medicine Co.,Ltd. ( Pill (15 pills/plate ×2 plates/box))
Study: NCT05434065
Drug: Celecoxib 200mg
Normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Using celecoxib (200 mg/day) for 21 days starting within 6 hours after onset of ICH
Study: NCT06609070
Drug: CHG0521 Oral Coating
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive an oral coating of CHG0521 in the form of drops, in addition to the clinician\&#39;s standard treatment regimen, for a duration of 6 months or until confirmed progression, unacceptable toxicity, or any criteria for withdrawal from the trial.
Study: NCT05392790
Drug: Calcium and Vit D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional medical treatment in the form of Calcium, Vit D and Bi phosphnate.
Study: NCT05179668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally once daily
Study: NCT05969756
Drug: Conventional etch and rinse sealant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thirty-eight permanent molars will receive conventional etch and rinse sealant
Study: NCT05145764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated placebo (matched for color, weight, and size)
Study: NCT05453942
Drug: SAR441566
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated dose of SAR441566 administered twice a day (BID) for 4 weeks under fed conditions
Study: NCT05453942
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated dose of matching placebo administered twice a day (BID) for 4 weeks under fed condition
Study: NCT06345482
Drug: MHB039A
Approvals — FDA: no, EMA: no, PMDA: no
Description: a bispecific antibody
Study: NCT05498233
Drug: Doxylamine + Pyridoxine
Normalized name: doxylamine / pyridoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of R or T drug in each of 2 periods of the study in fasted conditions
Study: NCT04960930
Drug: FMX101
Approvals — FDA: no, EMA: no, PMDA: no
Description: topically once daily
Study: NCT05108454
Drug: Multiple micronutrient supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple Micronutrient Supplements (MMS) is a nutritional supplement for use during pregnancy based on United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) formulation following WHO specification. It contains 15 micronutrients including Iron and Folic Acid (IFA) at dosages that approximate the recommended dietary allowances for pregnancy.
Study: NCT06009237
Drug: Placebo for ABBV-903
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; oral
Study: NCT04742348
Drug: Carbidopa Levodopa
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who are randomized to active drug group will receive 1 dose of immediate release carbidopa-levodopa (50mg/500mg) .
Study: NCT04742348
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who are randomized to placebo group will be provided with similar looking tablet(s) as the active drug.
Study: NCT05460364
Drug: BR1018-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group A : One tablet of BR1018-1 administered alone once daily for 9 days.~Treatment group C : One tablet each of BR1018-1 and BR1018-2 administered in combination once daily for 9 days.
Study: NCT05460364
Drug: BR1018-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group B : One tablet of BR1018-2 administered alone once daily for 9 days.~Treatment group C : One tablet each of BR1018-1 and BR1018-2 administered in combination once daily for 9 days.
Study: NCT06345794
Drug: LY4100511 (DC-853)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05893771
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided genicular nerve infiltration with 20 ml normal saline as a placebo control.
Study: NCT05098938
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral (upper gum area), 1 table.
Study: NCT05804513
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: s/c injection
Study: NCT04999215
Drug: F-choline intravenous injection
Normalized name: choline Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive one injection of F-choline before undergoing hybrid PET/CT imaging per standard procedures. F-choline PET examinations may be repeated, if this judged to be in the patient's best interest by his referring physician and the study staff, up to a maximum 4 examinations per year.
Study: NCT04765644
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two 200 mg capsules per day (400 mg/day) for 7 days